GW-501516, also known as Cardarine, is a PPAR receptor agonist developed by Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s. Initially created to treat obesity, diabetes, lipid imbalance, and cardiovascular diseases, GW-501516 has been shown to improve cholesterol levels significantly when users run blood work during its use.
PPAR receptor agonists are drugs that activate genes responsible for the metabolism of glucose and fatty acids.